Free Trial
→ The case for $20,000 gold before year end (From Stansberry Research) (Ad)tc pixel Free MDNA Stock Alerts

Medicenna Therapeutics (MDNA) Competitors

Medicenna Therapeutics logo
C$0.41 +0.03 (+6.49%)
As of 10/5/2026 01:24 PM Eastern
Compare

MDNA vs. COV, SCYB, COM, NVH, and HBP

Should you buy Medicenna Therapeutics stock or one of its competitors? Medicenna Therapeutics's main competitors and comparable companies include Covalon Technologies (COV), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), and Helix BioPharma (HBP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Medicenna Therapeutics compare to Covalon Technologies?

Medicenna Therapeutics (TSE:MDNA) and Covalon Technologies (CVE:COV) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

0.4% of Medicenna Therapeutics shares are held by institutional investors. Comparatively, 0.2% of Covalon Technologies shares are held by institutional investors. 22.6% of Medicenna Therapeutics shares are held by company insiders. Comparatively, 48.7% of Covalon Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Medicenna Therapeutics has a beta of 3.001413, meaning that its stock price is 200% more volatile than the broader market. Comparatively, Covalon Technologies has a beta of 1.397953, meaning that its stock price is 40% more volatile than the broader market.

Covalon Technologies has a net margin of 12.78% compared to Medicenna Therapeutics' net margin of -533,640.00%. Covalon Technologies' return on equity of 15.04% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Medicenna Therapeutics-533,640.00% -360.29% -32.80%
Covalon Technologies 12.78%15.04%-3.25%

In the previous week, Medicenna Therapeutics had 2 more articles in the media than Covalon Technologies. MarketBeat recorded 2 mentions for Medicenna Therapeutics and 0 mentions for Covalon Technologies. Medicenna Therapeutics' average media sentiment score of 0.74 beat Covalon Technologies' score of 0.51 indicating that Medicenna Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Medicenna Therapeutics Positive
Covalon Technologies Positive

Covalon Technologies has higher revenue and earnings than Medicenna Therapeutics. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than Covalon Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.22N/A
Covalon TechnologiesC$34.35M3.49C$2.39MC$0.1627.13

Summary

Covalon Technologies beats Medicenna Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Medicenna Therapeutics compare to Scythian Biosciences?

Scythian Biosciences (CVE:SCYB) and Medicenna Therapeutics (TSE:MDNA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

0.4% of Medicenna Therapeutics shares are owned by institutional investors. 22.6% of Medicenna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Scythian Biosciences has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. Scythian Biosciences' return on equity of 0.00% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Scythian BiosciencesN/A N/A N/A
Medicenna Therapeutics -533,640.00%-360.29%-32.80%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scythian BiosciencesN/AN/AN/AN/AN/A
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.22N/A

In the previous week, Medicenna Therapeutics had 2 more articles in the media than Scythian Biosciences. MarketBeat recorded 2 mentions for Medicenna Therapeutics and 0 mentions for Scythian Biosciences. Medicenna Therapeutics' average media sentiment score of 0.74 beat Scythian Biosciences' score of 0.00 indicating that Medicenna Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Scythian Biosciences Neutral
Medicenna Therapeutics Positive

Summary

Medicenna Therapeutics beats Scythian Biosciences on 4 of the 7 factors compared between the two stocks.

How does Medicenna Therapeutics compare to 138267 (COM.TO)?

Medicenna Therapeutics (TSE:MDNA) and 138267 (COM.TO) (TSE:COM) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.22N/A
138267 (COM.TO)N/AN/AN/AN/AN/A

138267 (COM.TO) has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. 138267 (COM.TO)'s return on equity of 0.00% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Medicenna Therapeutics-533,640.00% -360.29% -32.80%
138267 (COM.TO) N/A N/A N/A

0.4% of Medicenna Therapeutics shares are owned by institutional investors. 22.6% of Medicenna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Medicenna Therapeutics had 2 more articles in the media than 138267 (COM.TO). MarketBeat recorded 2 mentions for Medicenna Therapeutics and 0 mentions for 138267 (COM.TO). Medicenna Therapeutics' average media sentiment score of 0.74 beat 138267 (COM.TO)'s score of 0.00 indicating that Medicenna Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Medicenna Therapeutics Positive
138267 (COM.TO) Neutral

Summary

Medicenna Therapeutics beats 138267 (COM.TO) on 4 of the 7 factors compared between the two stocks.

How does Medicenna Therapeutics compare to Novoheart?

Novoheart (CVE:NVH) and Medicenna Therapeutics (TSE:MDNA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

Novoheart has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. Novoheart's return on equity of 0.00% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
NovoheartN/A N/A N/A
Medicenna Therapeutics -533,640.00%-360.29%-32.80%

In the previous week, Medicenna Therapeutics had 2 more articles in the media than Novoheart. MarketBeat recorded 2 mentions for Medicenna Therapeutics and 0 mentions for Novoheart. Medicenna Therapeutics' average media sentiment score of 0.74 beat Novoheart's score of 0.00 indicating that Medicenna Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Novoheart Neutral
Medicenna Therapeutics Positive

Novoheart has higher revenue and earnings than Medicenna Therapeutics. Novoheart is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NovoheartC$423.50K236.08-C$7.17M-C$0.04N/A
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.22N/A

0.4% of Medicenna Therapeutics shares are owned by institutional investors. 22.6% of Medicenna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Novoheart beats Medicenna Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Medicenna Therapeutics compare to Helix BioPharma?

Helix BioPharma (TSE:HBP) and Medicenna Therapeutics (TSE:MDNA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

Helix BioPharma is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.22N/A

Helix BioPharma has a beta of 0.722962, meaning that its share price is 28% less volatile than the broader market. Comparatively, Medicenna Therapeutics has a beta of 3.001413, meaning that its share price is 200% more volatile than the broader market.

0.0% of Helix BioPharma shares are owned by institutional investors. Comparatively, 0.4% of Medicenna Therapeutics shares are owned by institutional investors. 2.2% of Helix BioPharma shares are owned by insiders. Comparatively, 22.6% of Medicenna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Medicenna Therapeutics had 2 more articles in the media than Helix BioPharma. MarketBeat recorded 2 mentions for Medicenna Therapeutics and 0 mentions for Helix BioPharma. Medicenna Therapeutics' average media sentiment score of 0.74 beat Helix BioPharma's score of 0.31 indicating that Medicenna Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Helix BioPharma Neutral
Medicenna Therapeutics Positive

Helix BioPharma has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. Helix BioPharma's return on equity of -21.54% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A -21.54% -279.98%
Medicenna Therapeutics -533,640.00%-360.29%-32.80%

Summary

Medicenna Therapeutics beats Helix BioPharma on 8 of the 11 factors compared between the two stocks.

Get Medicenna Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MDNA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MDNA vs. The Competition

Export
MetricMedicenna TherapeuticsBiotechnology IndustryHealthcare SectorTSE Exchange
Market CapC$37.84MC$3.85BC$7.14BC$12.54B
Dividend YieldN/A3.65%2.53%6.33%
P/E Ratio-1.8612.99274.3239.51
Price / SalesN/A1,294.29609.249.07
Price / Cash1.1539.0427.2282.29
Price / Book21.2317.0611.234.48
Net Income-C$25.98M-C$23.20MC$3.49BC$299.09M
7 Day Performance3.80%-2.14%-1.31%-0.29%
1 Month Performance-12.77%-10.22%-5.97%-2.86%
1 Year Performance-56.84%17.47%7.26%15.06%

Medicenna Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MDNA
Medicenna Therapeutics
N/AC$0.41
+6.5%		N/A-58.6%C$37.84MN/AN/A20
COV
Covalon Technologies
N/AC$3.98
+2.6%		N/A+105.7%C$109.92MC$34.35M24.88N/A
SCYB
Scythian Biosciences
N/AC$3.49
-5.9%		N/A+0.0%C$102.38MN/AN/AN/A
COM
138267 (COM.TO)
N/AN/AN/AN/AC$102.19MN/AN/AN/A
NVH
Novoheart
N/AC$0.53
+1.9%		N/A+0.0%C$99.98MC$423.50KN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:MDNA) was last updated on 10/6/2026 by MarketBeat.com Staff.
From Our Partners
This smart glasses tech is bringing the screen to your eyes
Global AI smart-glasses shipments surged 263% in the first half of 2026, and Citi projects the market could re...
The Tomorrow Investor | Sponsoredtc pixel
Musk says UBI is coming. I say it's already here.
Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...
Freedom Financial | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
I've seen this movie before (last time: 17,556%)
My track record speaks for itself... KDA: 17,556%. PRE: 3,900%. OCEAN: 2,650%. Every single one was called ...
Crypto 101 Media | Sponsoredtc pixel
The case for $20,000 gold before year end
President Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and A...
Stansberry Research | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel